SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moore Matthew Richard
(Last) (First) (Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300
(Street)
WESTLAKE VILLAGE CA 91361
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP and Chief Business Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2024 A 26,666 A (1) 81,256 D
Common Stock 02/13/2024 A 26,666 A (1) 107,922 D
Common Stock 02/13/2024 A 17,650 A (2) 125,572 D
Common Stock 02/13/2024 A 19,750 A (3) 145,322 D
Common Stock 02/13/2024 A 4,166 A (4) 149,488 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $28.72 02/13/2024 D 80,000 (5) 01/19/2031 Common Stock 80,000 (1) 0 D
Stock Option (Right to Buy) $28.72 02/13/2024 D 80,000 (6) 01/19/2031 Common Stock 80,000 (1) 0 D
Stock Option (Right to Buy) $17.67 02/13/2024 D 35,300 (7) 03/03/2032 Common Stock 35,300 (2) 0 D
Stock Option (Right to Buy) $15.82 02/13/2024 D 39,500 (8) 03/02/2033 Common Stock 39,500 (3) 0 D
Stock Option (Right to Buy) $28.72 02/13/2024 D 12,500 (9) 01/18/2031 Common Stock 12,500 (4) 0 D
Explanation of Responses:
1. On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024.
2. On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
3. On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024.
4. On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, performance-based option granted to the Reporting Person on January 19, 2021, and deemed earned on August 29, 2023, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
5. The canceled option vested as to 1/4 of the total shares on July 20, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on July 20, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
6. The canceled option vested as to 1/4 of the total shares on January 11, 2022, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on January 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
7. The canceled option vested as to 1/48 of the shares vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
8. The canceled option vested as to 1/48 of the shares vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
9. The canceled option vested as to 1/48 of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Remarks:
/s/ John W. Smither, Attorney-in-Fact for Matthew Richard Moore 02/15/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arcutis Biotherapeutics Charts.
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arcutis Biotherapeutics Charts.